|Articles|February 12, 2021

Experience the Art of Science on Your Drug Development Project with Pfizer CentreOne®

Pfizer CentreOne® is a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Visit www.pfizercentreone.com.

Pfizer CentreOne has years of drug development experience and there are few challenges we haven’t faced. We leverage our development and tech transfer expertise to guide your product through milestones and overcome project challenges to take you further.

Worldwide, our sites have been developing and manufacturing Pfizer’s broad array of innovative molecules for decades, and this legacy helps ensure a successful collaboration with you:

We offer the knowledge, network, and expert legacy to act as your creative problem solver and collaborative partner on your drug development project.

We offer an expert suite of development and optimization services in formulation, clinical drug manufacturing, analytical testing, validation, and method development.

Access our wide-range of capabilities to support today’s therapeutic trends:

  • Small molecule APIs
  • Large molecule biologics
  • Oral solids
  • Sterile injectables

Pfizer CentreOne
pfizercentreone.com
pfizercentreone@pfizer.com


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.